Agios Pharmaceuticals, Inc. AGIO

AGIO Company Overview

Agios Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company focused on discovering, developing, and commercializing therapies for rare diseases driven by dysregulated cellular metabolism. The company operates within the biotechnology and pharmaceuticals industry, with a strategic emphasis on genetically defined hematologic conditions. Its primary revenue drivers include sales of its approved rare disease therapy and ongoing royalty and milestone income from previously divested oncology assets.

Agios was founded in 2008 to translate insights in cellular metabolism into novel medicines. The company initially built a broad oncology portfolio but underwent a major strategic transformation beginning in 2020, culminating in the divestiture of its oncology business to Servier Pharmaceuticals in 2021. Following this transaction, Agios repositioned itself as a pure-play rare disease company, centering its long-term strategy on metabolic and hematologic disorders with high unmet medical need.